Immunome Inc
IMNM
Market Cap$770.05M
Close$
$2.47
68% downside
Current Fair Value
68% downsideOvervalued by 68% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $770.05 Million |
|---|---|
| Enterprise Value | $638.48 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5 |
| Beta | 2.06 |
| Outstanding Shares | 62,703,987 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.89 |
|---|---|
| PEG | -0.19 |
| Price to Sales | - |
| Price to Book Ratio | 3.86 |
| Enterprise Value to Revenue | 63.03 |
| Enterprise Value to EBIT | -2.01 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Immunome Inc
2,020 employeesImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initi...